In this 24-week, prospective, non-interventional, observational study, effect on quality of life was assessed after patients with type 2 diabetes started or switched to an insulin analogue.

Authored by: Shah S, Zilov A, Malek R et al.

Added: 30/01/2012

Related Tags: basal, aspart, biphasic, detemir, insulin, treatment, type 2

A₁chieve is a non-interventional, 6-month observational study in 28 countries, across 4 continents. The efficacy and safety of insulin analogues, insulin detemir, aspart and biphasic, were assessed in the routine clinical care of 66726 people with type 2 diabetes.

Authored by: Home P, El Naggar N, Khamseh M et al.

Added: 30/01/2012

Related Tags: basal, aspart, biphasic, detemir, insulin, treatment, type 2

Ease of handling study to compare the perception, preference and ease of use for FlexTouch^® vs. KwikPen^TM among people with diabetes, physicians and nurses

Authored by: Bailey T et al.

Added: 30/01/2012

Related Tags: device, pen, treatment, dosing

Ease of handling study to compare the perception, preference and ease of use for FlexTouch^® vs. SoloStar^® among people with diabetes, physicians and nurses

Authored by: Oyer D et al.

Added: 30/01/2012

Related Tags: device, pen, treatment, dosing

A technical study comparing the injection force of FlexTouch^® vs SoloStar^® and KwikPen^™

Authored by: Hemmingsen H et al.

Added: 30/01/2012

Related Tags: device, pen, treatment, dosing

A technical study comparing dose accuracy and consistency of FlexTouch^® vs SoloStar^® and KwikPen^TM

Authored by: Wielandt JO et al.

Added: 30/01/2012

Related Tags: device, pen, treatment, dosing

Clinical trial to assess the efficacy, safety and preference for FlexTouch^® in comparison to FlexPen^®

Authored by: Garg S et al.

Added: 30/01/2012

Related Tags: device, pen, treatment, dosing

A technical study comparing dose force and dose accuracy of FlexTouch^® vs Next Generation FlexPen^®

Authored by: Wieland et al.

Added: 30/01/2012

Related Tags: device, pen, treatment, dosing

An analysis of a treatment satisfaction from a 26-week, randomised, open-label trial comparing liraglutide to another widely used type 2 diabetes treatment.

Authored by: Davies M, et al.

Added: 30/01/2012

Related Tags: liraglutide, treatment, type 2, GLP-1

Analysis from studies that show the effect of mild renal impairment (RI) on the efficacy and safety of liraglutide in patients with type 2 diabetes.

Authored by: Davidson, et al.

Added: 30/01/2012

Related Tags: type 2, liraglutide, hypoglycaemia

A 52-week randomised, multinational, open-label trial investigated the use of insulin detemir compared to NPH in 2-16 year olds with type 1 diabetes. Discover the efficacy and safety profile of these basal insulins in a subgroup analysis of 2-5 year olds.

Authored by: Thalange N et al.

Added: 19/12/2011

Related Tags: Basal, complications, hypoglycaemia, insulin, type 1, paediatrics

These trials evaluated rates of antibody formation with two GLP-1 agonists and the effects of antibodies on glycaemic control and safety.

Authored by: Buse, et al.

Added: 19/12/2011

Related Tags: liraglutide, patient, type 2

A 14-week extension of LEAD 6 focusing on the efficacy and safety of liraglutide in patients switching from the GLP-1 agonist exenatide.

Authored by: Buse, et al.

Added: 19/12/2011

Related Tags: liraglutide, hypoglycaemia, GLP-1

A study focusing on whether or not GLP-1 receptor agonists activate rodent thyroid C-cells.

Authored by: Knudsen, et al.

Added: 19/12/2011

Related Tags: mechanism, GLP-1

Analysis of calcitonin levels from a series of clinical studies comparing the efficacy of liraglutide with placebo or a variety of standard therapies in more than 5000 patients with type 2 diabetes mellitus or nondiabetic obese subjects.

Authored by: Hegedus, et al.

Added: 19/12/2011

Related Tags: weight, type 2, treatment, GLP-1

A randomised, controlled, parallel-group, open-label, 48 week trial comparing stepwise addition of insulin aspart to either the largest meal or to the meal with the largest prandial glucose increment.

Authored by: Meneghini LF, Hermansen K, et al.

Added: 06/11/2011

Related Tags: treatment, basal, titration, insulin, aspart, detemir

A 52-week, open-label, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in people with type 2 diabetes.

Authored by: Hollander P; Cooper J; et al.

Added: 07/12/2010

Related Tags: glycaemic target, basal, detemir, insulin, type 2, titration, dosage, HbA1c, bolus, intensification, aspart

A double-blind, randomized, crossover study assessing 24-hour glycaemic control with once-daily insulin detemir or once-daily insulin glargine in patients with type 2 diabetes.

Authored by: King AB

Added: 10/01/2011

Related Tags: glycaemic target, basal, detemir, insulin, type 2, treatment, HbA1c, blood glucose

The objective of this study was to examine the options for add-on therapy in patients with type 2 diabetes whose disease was no longer adequately controlled by lifestyle interventions and oral antidiabetic drug monotherapy.

Authored by: Nauck M et al.

Added: 17/03/10

Related Tags: liraglutide, oral antidiabetic, patient, type 2, weight

A randomised, 34-week, parallel-group study assessing the effect of adding biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of insulin-naïve, type 2 diabetes patients.

Authored by: Raskin et al. Diabet Obes Metab 2009;11(1):27-32

Added: 07/02/2011

Related Tags: insulin, type 2, HbA1c, biphasic, oral antidiabetic, glycaemic target, aspart, premix, glargine

Time-action profiles of the novel albumin-bound basal insulin analogue NN344 with those of insulin detemir and insulin glargine in individuals with type 2 diabetes.

Authored by: Klein et al.

Added: 17/03/2010

Related Tags: basal, detemir, insulin, type 2

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.

Authored by: Rosenstock et al.

Added: 17/03/2010

Related Tags: function, GLP-1, insulin, liraglutide, patient, type 2, weight, hypoglycaemia

A review of prandial glucose regulation with the insulin secretagogue, repaglinide, and flexible approaches to managing type 2 diabetes.

Authored by: Natrass and Lauritzen, 2000

Added: 18/01/2011

Related Tags: prandial, type 2, management, oral antidiabetic, treatment

An open-label, 7-month study comparing the effects of once versus twice-daily administration of insulin detemir, plus mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes.

Authored by: Le Floch JP; Lévy M; et al.

Added: 10/01/2011

Related Tags: glycaemic target, basal, detemir, insulin, type 1, treatment, titration, dosage, HbA1c, blood glucose, bolus, aspart

This article reviews published evidence of patient-reported outcomes associated with insulin therapy over the past 3 decades in patients with type 1 and type 2 diabetes who used vial and syringe for insulin delivery compared to those who used insulin pens.

Authored by: Molife C et al.

Added: 17/03/10

Related Tags: insulin, patient, pen, type 1, type 2

A survey assessing patient perceptions of glycaemic control, convenience, and flexibility of a prescribed prandial oral therapy for type 2 diabetes.

Authored by: Bonneville, 2001

Added: 18/01/2011

Related Tags: prandial, type 2, management, medication, oral antidiabetic, glycaemic target, patient, treatment

Observational study in patients with type 2 diabetes failing oral agent therapy with or without basal insulin conducted to assess whether addition and self-titration of biphasic insulin aspart 70/30 (BIAsp 30) could achieve IDF and ADA glycaemic targets.

Authored by: Garber et al.

Added: 17/03/2010

Related Tags: aspart, basal, biphasic, glycaemic target, insulin, patient, premix, titration, type 2

A 26-week, randomised, treat-to-target trial, comparing insulin detemir once-daily plus prandial insulin aspart or biphasic insulin aspart 30 twice-daily in type 2 diabetes patients discontinuing OADs.

Authored by: Liebl A et al. Diabetes Obes Metab 2009; 1: 45-52

Added: 07/02/2011

Related Tags: glycaemic target, insulin, type 2, HbA1c, biphasic, tolerability, blood glucose, basal, prandial, bolus, oral antidiabetic, intensification, aspart, premix

In this study, injection force requirements and dosage scale displays were evaluated for two durable insulin pens.

Authored by: Donsmark M et al.

Added: 17/03/10

Related Tags: dosage, insulin, needle, pen, novopen 4

Compare the effectiveness and tolerability of insulin detemir versus NPH administered QD together with at least one OAD in poorly controlled type 2 diabetes and the different administration times of insulin detemir.

Authored by: Philis-Tsimikas et al.

Added: 17/03/2010

Related Tags: basal, detemir, insulin, oral antidiabetic, tolerability, type 2

This handling study compared preference and usability of three durable insulin pens among diabetes physicians, diabetes nurses, and patients with diabetes.

Authored by: Kolaczynski M and Chayer D

Added: 17/03/10

Related Tags: insulin, patient, pen, novopen 4

Compare the dosing accuracy of two prefilled insulin pens at dosages of 10 IU and 30 IU.

Authored by: Weise et al.

Added: 17/03/2010

Related Tags: accuracy, dosage, insulin, pen

A randomised, 36-week trial evaluating the clinical efficacy and safety of biphasic insulin aspart 30 twice daily versus high-mix regimens thrice daily in combination with metformin in subjects with type 2 diabetes.

Authored by: Cucinotta D et al. Diabetes Obes Metab 2009;11(7):700-8

Added: 07/02/2011

Related Tags: prandial, insulin, type 2, HbA1c, biphasic, oral antidiabetic, tolerability, aspart, premix

This open label study compared the usability and patient preference for thin wall needles versus regular wall needles designed for use with insulin pens.

Authored by: Siegmund

Added: 17/03/10

Related Tags: insulin, needle, patient, pen

Study investigating if there were any differences in weight development when using insulin detemir or NPH, according to subjects’ BMI.

Authored by: Philis-Tsimikas et al.

Added: 17/03/2010

Related Tags: basal, detemir, insulin, weight

A 26-week, open-label, randomised, treat-to-target trial comparing the once-daily initiation of insulin with biphasic insulin aspart 30 versus insulin glargine in subjects with type 2 diabetes inadequately controlled with OADs.

Authored by: Strojek K et al. Current Medical Research & Opinion Vol. 25, No. 12, 2009, 2887-2894

Added: 07/02/2011

Related Tags: insulin, type 2, HbA1c, biphasic, oral antidiabetic, glycaemic target, blood glucose, aspart, premix

A 28-week, randomised, parallel-group study comparing the safety and efficacy of twice-daily biphasic insulin aspart 70/30 with once-daily insulin glargine in patients with type 2 diabetes subjects inadequately controlled on OADs.

Authored by: Raskin P et al. Diabetes Care 28:260–265, 2005

Added: 07/02/2011

Related Tags: basal, detemir, insulin, type 2, treatment, HbA1c, blood glucose, bolus, tolerability, biphasic, oral antidiabetic, aspart, premix, glargine

Tight glycaemic control may be compromised by weight gain and the risk of hypoglycaemia. Clarify the weight effect of each of the currently available diabetes medications, and explore the mechanism of action behind this effect.

Authored by: Mitri et al.

Added: 17/03/2010

Related Tags: hypoglycaemia, insulin, mechanism of action, medication, oral antidiabetic, weight, glycaemic target

Compare the dosing accuracy of four commonly available insulin pens used by children and adults with type 1 and type 2 diabetes.

Authored by: Hänel et al.

Added: 17/03/2010

Related Tags: accuracy, device, insulin, pen, type 1, type 2

In this study, the dose accuracy of a durable insulin pen was evaluated before and after simulation of 5 years use and under conditions of mechanical and temperature stress.

Authored by: Kristensen CM and Donsmark M.

Added: 13/04/2010

Related Tags: accuracy, aspart, biphasic, device, hypoglycaemia, insulin, pen, type 2, glycaemic target, novopen 4

Determine the dose accuracy of two commonly available prefilled insulin pens for use in diabetes.

Authored by: Asakura et al.

Added: 17/03/10

Related Tags: accuracy, device, insulin, pen

6-week pilot study investigating the long-term effects of continuous administration of glucagon-like peptide (GLP-1).

Authored by: Zander et al.

Added: 17/03/2010

Related Tags: function, insulin, type 2, glycaemic target, GLP-1

Randomized, multi-centre, double-blind, stratified, two period, crossover trial undertaken to assess the pharmacokinetics and pharmacodynamics of insulin aspart injected immediately before compared with regular human insulin injected 30 min before a Mediterranean-style meal in patients with type 2 diabetes.

Authored by: Perriello et al.

Added: 17/03/2010

Related Tags: aspart, insulin, patient, prandial, type 2, glycaemic target

Post hoc subanalysis of a multi-national, open-label, prospective, observational study assessing the safety and efficacy of insulin detemir in clinical practice evaluates insulin-naïve patients on oral antidiabetic drugs (OADs) who were initiated on insulin detemir as basal therapy (± OADs).

Authored by: Dornhorst et al.

Added: 17/03/2010

Related Tags: detemir, insulin, oral antidiabetic, patient, type 2, weight, glycaemic target

A 26-week, multinational, open-label, study comparing the efficacy and safety of a basal-bolus insulin regimen with either insulin detemir or NPH insulin in combination with mealtime insulin aspart in patients with type 2 diabetes.

Authored by: Haak T; Tiengo A; et al.

Added: 10/01/2011

Related Tags: glycaemic target, basal, detemir, insulin, type 2, treatment, titration, dosage, HbA1c, blood glucose, bolus, weight, aspart

A randomized, open-label, 16-week study comparing the efficacy of insulin detemir versus NPH insulin in people with type 1 diabetes.

Authored by: Home P; Bartley P; et al.

Added: 10/01/2011

Related Tags: basal, detemir, insulin, type 1, treatment, HbA1c, blood glucose

A 6-month, prospective, randomized, open-label trial assessing the effects of once-daily basal insulin replacement using insulin detemir versus NPH insulin in basal-bolus therapy combined with regular human insulin in patients with type 1 diabetes.

Authored by: Russell-Jones D; Simpson R; et al.

Added: 10/01/2011

Related Tags: basal, detemir, insulin, type 1, treatment, HbA1c, bolus, dosage

The efficacy and safety of adding liraglutide (a glucagon-like peptide-1 receptor agonist) to metformin compared with addition of placebo or glimepiride to metformin in patients with type 2 diabetes previously treated with oral antidiabetes (OAD) therapy.

Authored by: Nauck et al.

Added: 17/03/2010

Related Tags: liraglutide, patient, rosiglitazone, type 2, oral antidiabetic, GLP-1

28-week, randomised, multicenter, open-label, parallel-group phase III trial to investigate the efficacy and safety of biphasic insulin aspart 70 thrice-daily injections vs twice-daily injections of biphasic insulin aspart 30 in patients with type 2 diabetes.

Authored by: Kadowaki T et al. J Diabetes Invest 2010: doi: 10.1111/j.2040-1124.2010.00015.x, 2010

Added: 07/02/2011

Related Tags: aspart, biphasic, insulin

LEAD-4 Met + TZD: a 26-week, double-blind, placebo-controlled trial assessing the efficacy and safety of the GLP-1 receptor agonist, liraglutide, when added to metformin and rosiglitazone in type 2 diabetes.

Authored by: Zinman B et al.

Added: 18/01/2011

Related Tags: GLP-1, liraglutide, patient, rosiglitazone, type 2, tolerability, HbA1c, oral antidiabetic

26-week, double-blind, placebocontrolled, parallel-group trial to determine the efficacy and safety of liraglutide (a glucagon-like peptide-1 receptor agonist) when added to metformin and rosiglitazone in type 2 diabetes.

Authored by: Zinman et al.

Added: 17/03/2010

Related Tags: GLP-1, liraglutide, patient, rosiglitazone, type 2

This study compared the postprandial glycaemic control achieved with meal-related insulin aspart injected immediately before a meal with that injected immediately after a meal.

Authored by: Jovanovic

Added: 17/03/10

Related Tags: aspart, insulin, prandial, glycaemic target

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Authored by: Marre M et al.

Added: 13/12/2010

Related Tags: GLP-1, liraglutide, weight, rosiglitazone, type 2, hypoglycemia, HbA1c, blood glucose, oral antidiabetic

Examine the epidemiology of worry about weight among adults with diabetes and whether this weight worry was associated with worse quality of life and diabetes self-management.

Authored by: Peyrot et al.

Added: 17/03/2010

Related Tags: management, weight

26-week, randomised trial comparing the safety and efficacy of lirgalutide, placebo and insulin glargine, all as add-on treatment to metformin and glimepiride.

Authored by: Russell-Jones et al.

Added: 17/03/2010

Related Tags: insulin, liraglutide, treatment, weight, glycaemic target, GLP-1

Compare the injection force of three insulin delivery pens during injection of 20 U insulin at three speeds, using two types of needles.

Authored by: Asakura et al.

Added: 17/03/2010

Related Tags: insulin, needle, pen

Study investigating diabetes treatment satisfaction in patients with type 2 diabetes before and after treatment with bilphasic insulin aspart 70/30 (BIAsp 30).

Authored by: Yang et al.

Added: 17/03/2010

Related Tags: aspart, biphasic, insulin, patient, premix, treatment, type 2

This study assessed maternal and cord blood insulin antibody levels in a subset of pregnant women with type 1 diabetes who were treated with a rapid acting insulin analogue.

Authored by: D.R. McCance

Added: 17/03/10

Related Tags: aspart, insulin, pregnant, type 1

Injection force of two different prefilled insulin pens tested during the delivery of 60 IU insulin at three constant push-button speeds.

Authored by: Rissler et al.

Added: 17/03/2010

Related Tags: device, insulin, pen

Compare the efficacy and safety of twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride as starting regimens in insulin-naïve type 2 diabetes patients.

Authored by: P. Kann Exp Clin Endocrinol Diabetes 2006; 114: 527–532

Added: 07/02/2011

Related Tags: basal, detemir, insulin, type 2, HbA1c, tolerability, biphasic, oral antidiabetic, premix, glargine

Compare insulin aspart (IAsp) with human insulin (HI) in basal-bolus therapy with neutral protamine Hagedorn for fetal and perinatal outcomes of type 1 diabetes in pregnancy.

Authored by: Hod et al.

Added: 17/03/2010

Related Tags: aspart, basal, bolus, insulin, type 1

The incretin effect is attenuated in patients with type 2 diabetes, partly as a result of impaired beta cell responsiveness to glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This study investigated whether 4 weeks of near-normalisation of blood glucose level could improve insulin responses to GIP and GLP-1 in patients with type 2 diabetes.

Authored by: Højberg et al.

Added: 17/03/2010

Related Tags: blood glucose, incretin, insulin, patient, treatment, type 2, GLP-1

Compare the within-subject variability of the glucose-lowering effect of insulin detemir versus insulin glargine and NPH insulin in people with type 1 diabetes.

Authored by: Heise T; Nosek L; et al.

Added: 10/01/2011

Related Tags: basal, detemir, insulin, type 1, blood glucose

Glycaemic control and insulin utilisation in UK patients with type 2 diabetes initiated on either biphasic insulin aspart 30 or biphasic human insulin 30.

Authored by: Fakhoury W et al. Advanced therapy 2010 (published online)

Added: 07/02/2011

Related Tags: aspart, biphasic, insulin

The IMPROVE study: a 26-week, open-label, non-randomised, observational study evaluating the safety and efficacy of initiating biphasic insulin aspart 30/70 in type 2 diabetes patients uncontrolled on OADs.

Authored by: Wenying Y et al. Current Medical Research & Opinion Vol. 25, No. 11, 2009, 2643–2654

Added: 07/02/2011

Related Tags: insulin, type 2, HbA1c, biphasic, oral antidiabetic, tolerability, aspart, premix

A German subgroup of the PREDICTIVE study assessing the safety and efficacy of initiating insulin detemir therapy or switching from NPH or insulin glargine in patients with type 2 diabetes in everyday clinical practice.

Authored by: Meneghini LF; Rosenberg KH; et al.

Added: 10/01/2011

Related Tags: glycaemic target, basal, detemir, insulin, type 2, treatment, titration, dosage, HbA1c

The IMPROVE 26-week, non-interventional observational study: evaluating the safety and efficacy of initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 in patients with type 2 diabetes in routine clinical practice.

Authored by: Valensi P et al. Int J Clin Pract, March 2009, 63, 3, 522-531

Added: 07/02/2011

Related Tags: insulin, type 2, HbA1c, blood glucose, biphasic, tolerability, patient, management, intensification, aspart, premix

A randomised, 18-week, open-label trial comparing the efficacy and tolerability of insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy in type 1 diabetes.

Authored by: Hermansen K; Fontaine P; et al.

Added: 10/01/2011

Related Tags: basal, detemir, insulin, type 1, treatment, HbA1c, blood glucose, bolus, tolerability, aspart

A 22-week, open-labelled, randomised study comparing basal-bolus therapy using either insulin detemir plus insulin aspart, or NPH insulin plus regular human insulin.

Authored by: Raslová K; Bogoev M; et al.

Added: 10/01/2011

Related Tags: glycaemic target, basal, detemir, insulin, type 2, treatment, titration, dosage, HbA1c, blood glucose, bolus, aspart

A retrospective cohort analysis comparing daily insulin use, glycaemic control and health care costs in insulin-naïve patients with type 2 diabetes who initiated treatment with either insulin detemir or insulin glargine.

Authored by: Borah BJ; Darkow T; et al.

Added: 10/01/2011

Related Tags: basal, detemir, insulin, type 2, treatment, HbA1c, dosage

Study (UKPDS 33) comparing the effects of intensive blood glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial.

Authored by: UK Prospective Diabetes Study (UKPDS) Group

Added: 17/03/2010

Related Tags: blood glucose, complications, insulin, patient, treatment, glycaemic target

Trial comparing the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day or placebo with glimepiride (2–4 mg/day) on glycaemic control, body weight and safety in type 2 diabetes.

Authored by: Marre et al.

Added: 17/03/2010

Related Tags: GLP-1, incretin, insulin, liraglutide, rosiglitazone, type 2, weight

Unlike most antihyperglycaemic drugs, glucagon-like peptide-1 (GLP-1) receptor agonists have a glucose-dependent action and promote weight loss. This study compared the effi cacy and safety of liraglutide, a human GLP-1 analogue, with exenatide, an exendin-based GLP-1 receptor agonist.

Authored by: Buse et al.

Added: 17/03/2010

Related Tags: GLP-1, liraglutide, type 2, weight

A 26-week, randomised, parallel-group, open-label trial comparing liraglutide versus sitagliptin for patients with type 2 diabetes with inadequate glycaemic control with metformin.

Authored by: Pratley

Added: 18/01/2011

Related Tags: GLP-1, liraglutide, type 2, HbA1c, blood glucose, oral antidiabetic

A randomised, controlled, multinational trial comparing the long-term safety and efficacy of twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30 over a 24 month period in patients with type 2 diabetes.

Authored by: Boehm B et al. Eur J Intern Med 2004; 15(8): 496–502.

Added: 07/02/2011

Related Tags: insulin, type 2, HbA1c, biphasic, tolerability, blood glucose, aspart, premix

Study was to assessing the safety and efficacy of insulin aspart (IAsp) versus regular human insulin (HI) in basal-bolus therapy with NPH insulin in pregnant women with type 1 diabetes.

Authored by: Mathiesen et al.

Added: 17/03/2010

Related Tags: aspart, basal, bolus, hypoglycaemia, insulin, pregnant, type 1

This review was designed to quantitate the effects of obesity and weight gain on risk for coronary heart disease (CHD) and to review the effects of weight loss on CHD risk factors.

Authored by: Anderson J and Konz E

Added: 17/03/2010

Related Tags: basal, insulin, management, weight

The IMPROVE observational study investigated the safety and efficacy of biphasic insulin aspart 30/70 in the routine treatment of patients with type 2 diabetes: this is a subgroup analysis of patients who switched from basal insulin.

Authored by: Gumprecht J et al. Int J Clin Pract, June 2009, 63, 6, 966-972

Added: 07/02/2011

Related Tags: insulin, type 2, HbA1c, biphasic, tolerability, blood glucose, basal, patient, treatment, management, aspart, premix

This study assessed the efficacy and safety of biphasic insulin aspart 70/30 and insulin glargine, administered once daily in people with type 2 diabetes inadequately controlled with oral antidiabetic drugs.

Authored by: Strojek K. et al., Curr Med Res Opin 2009

Added: 13/04/2010

Related Tags: aspart, basal, biphasic, insulin, oral antidiabetic, premix, type 2

Trial comparing safety and efficacy – including parental treatment satisfaction – of two basal–bolus regimens [IAsp plus Neutral Protein Hagedorn (NPH) insulin vs. regular human insulin (HI) plus NPH] in preschool children with type 1 diabetes.

Authored by: Danne et al.

Added: 17/03/2010

Related Tags: aspart, basal, bolus, insulin, prandial, treatment, type 1

Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE™ study.

Authored by: Blonde et al.

Added: 17/03/2010

Related Tags: basal, detemir, insulin, patient, titration, glycaemic target

Maintaining tight glycaemic control is an important issue for patients with type 2 diabetes. This review discusses the role of insulin in managing type 2 diabetes, patient education and counseling on insulin use and the features of newer insulin regimens and modern delivery devices.

Authored by: Rakel RE.

Added: 17/03/10

Related Tags: device, insulin, management, patient, pen, type 2, glycaemic target

This open-label, randomized, comparative crossover study assessed patient preference for two durable insulin pens.

Authored by: Asakura D et al.

Added: 17/03/10

Related Tags: device, insulin, needle, patient, pen

Study assessing injection force and patient perception of a prefilled insulin pen with design modifications aimed at reducing injection force. The accuracy and precision of the prefilled pen were also tested under standard conditions.

Authored by: Pfützner et al.

Added: 17/03/2010

Related Tags: accuracy, device, insulin, patient, pen, flexpen

The aim of this randomized, open-label, crossover study was to compare two types of needle design and diameter in patients with diabetes injecting insulin.

Authored by: Iwanaga M, Kamoi K.

Added: 17/03/10

Related Tags: insulin, needle, patient

Patient treatment satisfaction after switching to biphasic insulin aspart 30 in the IMPROVE study - an analysis of the influence of prior and current treatment factors.

Authored by: Brod M et al. Accepted for publication in Health Qual Life Outcomes (published online)

Added: 07/02/2011

Related Tags: aspart, biphasic, insulin

An overview of the available pharmacodynamic data of insulin detemir and insulin glargine derived using the glucose clamp technique.

Authored by: Heise T; Pieber TR

Added: 10/01/2011

Related Tags: basal, detemir, insulin, blood glucose